Compared to Estimates, Sotera Health (SHC) Q2 Earnings: A Look at Key Metrics
For the quarter ended June 2024, Sotera Health Company (SHC) reported revenue of $276.59 million, up 8.4% over the same period last year. EPS came in at $0.19, compared to $0.21 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $267.46 million, representing a surprise of +3.42%. The company delivered an EPS surprise of +11.76%, with the consensus EPS estimate being $0.17.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Revenues- Sterigenics
: $176.35 million versus $172.70 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change.
Net Revenues- Nelson Labs
: $59 million versus the two-analyst average estimate of $57.77 million. The reported number represents a year-over-year change of +4%.
Net Revenues- Nordion
: $41.24 million versus $37.72 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +29% change.
Segment Income- Sterigenics
: $96.78 million compared to the $93.60 million average estimate based on two analysts.
Segment Income- Nelson Labs
: $17.14 million compared to the $17.04 million average estimate based on two analysts.
Segment Income- Nordion
: $23.42 million compared to the $22.11 million average estimate based on two analysts.
View all Key Company Metrics for Sotera Health here>>>
Shares of Sotera Health have returned +12.5% over the past month versus the Zacks S&P 500 composite's -2.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sotera Health Company (SHC) : Free Stock Analysis Report